Abbott Defeated In HCV Patent Feud

Law360, New York (September 5, 2006, 12:00 AM EDT) -- Proving that its optimism was well-founded, Belgian biotechnology company Innogenetics N.V. has been handed a victory in its long-running battle with Abbott Laboratories over a hepatitis C virus genotyping patent.

On Friday, a jury in the U.S. District Court for the Western District of Wisconsin upheld Innogenetics' HCV patent, ruling that the intellectual property in dispute was valid.

"We are very gratified with the jury's decision that affirmed the validity of a very important patent to our company,” said Innogenetics Chief Executive Frank Morich. “We are...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.